Mainstream

Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial

Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial

Post Contentorka, abbvRead More

You might also be interested in reading Workers in volatile economies most likely to take pay in crypto: Report.

September 17, 2025
In Mainstream